U.S. General Merchandise and Department Stores Stock News

NYSE:SPXC
NYSE:SPXCMachinery

SPX Technologies (SPXC) Draws Fresh Analyst Interest As Fair Value Questions Linger

Fresh interest in SPX Technologies (SPXC) has been sparked by recent analyst research that highlights strong agreement on the company’s earnings potential. This renewed focus gives investors a reason to revisit the stock’s fundamentals. At a latest share price of $205.28, SPX Technologies has seen its 90 day share price return decline 5.25%, yet its 1 year total shareholder return of 7.40% and 3 year total shareholder return of about 1.6x indicate longer term momentum has been strong. Compare...
NasdaqGM:NBN
NasdaqGM:NBNBanks

Northeast Bank (NBN) Stock Stays Cheap Following Its 286% Five Year Run

Northeast Bank has produced very strong multi year returns, yet the stock still screens as undervalued on broad valuation checks. This raises a practical question for investors about how much of the story is already reflected in the current share price. With no intrinsic value model in play here, the focus falls on the share performance record, current multiples and the overall value score. The stock has returned 286.2% over 5 years, which places Northeast Bank in the group of regional banks...
NYSE:RIG
NYSE:RIGEnergy Services

Transocean (RIG) Moved Higher, What Is Behind The Fresh Attention?

Why Transocean’s New Indian Drillship Contract Matters Transocean (RIG) recently announced a two year binding Letter of Award for its Dhirubhai Deepwater KG2 drillship with Oil and Natural Gas Corporation in India, a material operational contract valued at about $300 million. Against this contract news, Transocean’s share price has moved to $5.74, with a 30 day share price return of 15.03% and a year to date share price return of 35.38%. The 1 year total shareholder return of 85.16% contrasts...
NYSE:VRT
NYSE:VRTElectrical

AI Infrastructure Stocks Backed By Real Cash Flow

With Europe-wide inflation concerns pushing expectations for more ECB rate hikes, funding costs for large tech projects are in sharper focus. That makes the AI infrastructure story especially interesting today. Investors are paying closer attention to companies that already turn AI demand into cash flow, not just headlines. This article highlights three AI infrastructure stocks from our screener that align with that theme and may merit closer examination. The three stocks highlighted below...
NYSE:AGL
NYSE:AGLHealthcare

agilon health (AGL) Stock May Be Below Fair Value On Raised Guidance

Agilon health stock has had a very strong year so far, yet the valuation checks still point to shares screening cheap on several measures. For investors looking at agilon health today, the combination of a sharp year to date gain and a high value score raises questions about how much upside, if any, is already reflected in the price. Year to date, agilon health is up about 459%, which is an unusually large move that can leave the stock more sensitive to shifts in expectations. Recent news...
NYSE:CNH
NYSE:CNHMachinery

CNH Industrial (CNH) Stock Trades Near Fair Value After 22% Gain

CNH Industrial stock has delivered a 22.2% gain year to date, yet broader valuation checks suggest the shares are not an obvious bargain and trade close to what many would consider a fair range. The 22.2% year to date return signals improving sentiment toward CNH Industrial, even though the stock remains down over the past year and across longer multi year periods. Planned investment of ₹2,000 crore in India to expand tractor manufacturing capacity may support future earnings power. However,...
NYSE:CHWY
NYSE:CHWYSpecialty Retail

Should Chewy’s Vet Clinic Push and Autoship Dependence Reshape Long-Term Cash Flows for CHWY Investors?

Chewy has recently come back into focus ahead of its now-completed September 9, 2026 fiscal second-quarter earnings report, with investors weighing its expansion into Chewy Vet Care Clinics and continued dependence on Autoship subscriptions. The tension between Chewy’s relatively high valuation multiples and its push into the multi-billion-dollar veterinary services market has become central to how investors assess its long-term cash-flow potential and execution risk. We’ll now explore how...
NasdaqGS:AVAV
NasdaqGS:AVAVAerospace & Defense

Could AeroVironment (AVAV) Be 33% Undervalued As NASA Mars Helicopter Deal Lands?

AeroVironment (AVAV) has attracted fresh attention after its MacCready Works team secured a NASA contract to co-design and co-manufacture three Mars helicopters for the SkyFall mission, which is planned for launch in late 2028. Despite the NASA SkyFall contract and recent defense orders, AeroVironment’s share price has come under pressure, with a year to date share price return down 40.6% and a 1 year total shareholder return down 38.8%, even though the 3 year total shareholder return is...
NasdaqGS:MDGL
NasdaqGS:MDGLBiotechs

Can Madrigal Pharmaceuticals (MDGL) Still Offer Value After Its Big Run?

Madrigal Pharmaceuticals has delivered very strong long term share price gains, yet the current valuation checks still lean toward the stock looking cheap on the broader scorecard. That combination raises questions for investors trying to judge whether recent trading levels already reflect the progress in the business. Over the past 5 years, Madrigal Pharmaceuticals has produced a very large total return, which puts extra focus on whether today’s price still leaves room for further value...
NYSE:LLY
NYSE:LLYPharmaceuticals

Eli Lilly (LLY) Wins FDA Approval For Mounjaro Heart Risk Reduction

Eli Lilly (NYSE: LLY) received FDA approval for Mounjaro to reduce major cardiovascular risk in adults with type 2 diabetes who are at high risk. The new indication expands Mounjaro’s approved use beyond blood sugar control to include cardiovascular risk reduction. The decision could influence how clinicians position Mounjaro in care plans for adults with type 2 diabetes and elevated cardiovascular risk. Payers may factor the cardiovascular indication into future coverage and reimbursement...
NasdaqGS:AAPL
NasdaqGS:AAPLTech

Apple (AAPL), Why Is The Latest Update Drawing So Much Attention?

Apple (AAPL) has pushed its AI hardware story forward with the launch of M6 and M5 Ultra chips in new Mac mini and Mac Studio models, sharpening investor focus on on-device AI capabilities. Apple’s share price has moved around this year, with a 1-day share price return of 0.36% and a 7-day share price return of 1.05%, while the 30-day share price return is down 7.5% after a strong year-to-date gain of 16.08%. Over longer periods, total shareholder return shows solid wealth creation, with a...
NasdaqGS:META
NasdaqGS:METAInteractive Media and Services

Meta Platforms (META) Settles Youth Safety Claims, Is The Valuation Gap Too Wide?

Meta Platforms (META) just agreed to pay up to US$18b over ten years to settle youth safety claims, while also locking in stricter teen time limits and new content controls across Facebook and Instagram. Despite the settlement, Meta Platforms’ recent share price performance has been mixed, with a 7 day share price return of 4.63% but a year to date share price decline of 12.19%. The 3 year total shareholder return of 94.71% contrasts with a 1 year total shareholder return decline of 23.72%,...
NasdaqGS:DIOD
NasdaqGS:DIODSemiconductor

Does Diodes (DIOD) Look Reasonable After The ElevATE Deal?

Diodes stock has logged a strong run so far this year, yet the broader valuation checks suggest the shares no longer look like a clear bargain. With the stock already up sharply, investors are weighing how much of the recent optimism is already reflected in the current price. Year to date the stock has returned 76.7%, which raises the bar for any further gains to be supported by fundamentals rather than momentum alone. The completed acquisition of ElevATE Semiconductor may support...
NYSE:WES
NYSE:WESOil and Gas

Is Western Midstream Partners (WES) Fully Valued After Its Solitude Pipeline Joint Venture?

Western Midstream Partners (WES) is drawing attention after joining the Solitude Pipeline System joint venture. The venture has approved construction of two long-haul natural gas pipelines from the Permian Basin to Katy, Texas. For context, Western Midstream Partners’ share price has eased slightly in the past week, with a 7 day share price return of 1.73% and a 1 day move lower, even as the 90 day share price return of 11.52% and year to date gain of 20.37% point to building momentum. The 1...
NasdaqGS:ADP
NasdaqGS:ADPProfessional Services

Can Automatic Data Processing (ADP) Justify Its Price On AI And Hiring Momentum?

Automatic Data Processing (ADP) stock drew fresh attention after the company reported consecutive weekly increases in U.S. private-sector job additions and highlighted ongoing investments in AI-driven automation and global human capital management platforms. The recent updates on U.S. private-sector job additions and ADP’s AI-focused HCM investments arrive as the stock trades at US$284.68, with a 30-day share price return of 7.76% and a 90-day share price return of 28.33%, while the 1-year...
NYSE:BBY
NYSE:BBYSpecialty Retail

Best Buy (BBY) Raises Full Year Guidance As Ad Network Sales Near $1 Billion

Best Buy (NYSE: BBY) raised its full-year sales and profit guidance following stronger than expected second quarter results. The company highlighted rapid growth in its retail media business and expects ad network sales to approach US$1b in 2026. Management pointed to the ad network as an important source of diversified revenue beyond traditional electronics retail. To broaden your view across related opportunities in technology and retail, explore 55 AI infrastructure stocks. NYSE:BBY...
OTCPK:LKNC.Y
OTCPK:LKNC.YHospitality

Luckin Coffee (OTCPK:LKNC.Y) Dropped, So What Is Driving Attention Now?

Fresh interest in Luckin Coffee (OTCPK:LKNC.Y) has been triggered by recent analyst coverage highlighting higher earnings estimates and a top Zacks Rank. This has drawn attention to how the stock’s current pricing compares with those expectations. Over the past month Luckin Coffee has delivered a 30 day share price return of about 10%, although the share price has eased in the last week and is now at US$35.25. The 1 year total shareholder return is slightly negative and the 5 year total...
NasdaqGM:CRVS
NasdaqGM:CRVSBiotechs

Does Peer-Reviewed Phase 1 Soquelitinib Data Reshape The Bull Case For Corvus Pharmaceuticals (CRVS)?

Corvus Pharmaceuticals recently reported in Blood the final peer-reviewed Phase 1/1b data for its oral ITK inhibitor soquelitinib in advanced T cell lymphomas, showing durable responses, a median overall survival exceeding two years, and a favorable safety profile across multiple dose levels. The publication strengthens the scientific case for soquelitinib’s selective ITK inhibition and Th1-skewing mechanism, underpinning Corvus’s ongoing registration Phase 3 PTCL trial and broader...
NasdaqGS:NOVT
NasdaqGS:NOVTElectronic

Novanta (NOVT) Could Be 26% Below Fair Value On Strong Quarterly Results

Why Novanta’s strong quarter matters for shareholders now Novanta (NOVT) posted quarterly revenue that exceeded analyst expectations and issued EBITDA and revenue guidance above forecasts. Yet the stock has slipped since the report, which hints that investor expectations were already high. Over the past year, Novanta’s share price has moved sharply higher, with a year-to-date share price return of 30.15% and a 1-year total shareholder return of 22.51%. However, the 9.21% share price decline...
NYSE:LDOS
NYSE:LDOSProfessional Services

Is New AI Army Cyber Deal Reshaping The Investment Case For Leidos Holdings (LDOS)?

In recent days, Leidos Holdings, Inc. announced two new U.S. defense health and cyber contracts: a US$301,000,000, five-year Army network monitoring agreement and a US$56,000,000, 66‑month Naval Health Research Center award for behavioral health research and operational assessments. Together, these wins highlight how Leidos is tying advanced AI-enabled cyber defense with data-driven psychological health work, deepening its role in supporting military readiness across both digital and human...
NYSE:ECG
NYSE:ECGConstruction

How Rising Analyst Earnings Estimates At Everus Construction Group (ECG) Have Changed Its Investment Story

In recent days, analysts have revised their earnings estimates higher for Everus Construction Group, Inc. (NYSE: ECG), reflecting increased optimism about the company’s earnings outlook. This broad-based shift in expectations, paired with a top-tier Zacks Rank #1 (Strong Buy), suggests analysts see its earnings power differently than before. With analysts increasingly aligned in raising earnings estimates, we’ll now examine how this improved sentiment interacts with Everus Construction...
NYSE:VLO
NYSE:VLOOil and Gas

Valero Energy (VLO) Earnings Beat Raises The Question Of Whether The Stock Is Already Priced In

Valero Energy (VLO) attracted fresh attention after its second quarter 2026 results showed a large improvement in adjusted earnings per share and revenues, along with a top Zacks Rank based on expected earnings growth. Against this backdrop, Valero Energy’s share price has climbed to $346.59, supported by a 30 day share price return of 15.96% and a 90 day share price return of 41.57%. The 1 year total shareholder return of 134.15% shows how strong the recent momentum has been despite a small...
NasdaqGS:WDAY
NasdaqGS:WDAYSoftware

What Is Workday (WDAY) Gaining From Its New Compensation Data Integration?

Workday (NasdaqGS: WDAY) and Salary.com announced a certified integration that automates compensation data management for joint customers. The integration connects Workday Human Capital Management with Salary.com to synchronize job, employee, and pay data for compensation teams. Customers gain a direct link between internal compensation management and external market pricing data to support pay decisions. Early adoption from financial services firms highlights immediate interest from sectors...
NYSE:CHE
NYSE:CHEHealthcare

Chemed (CHE) Dropped, What Is Behind The Fresh Attention?

Chemed stock performance snapshot after recent price moves Chemed (CHE) has drawn fresh attention after recent price moves, with the stock last closing at US$520.27. That level reflects mixed short term returns and a stronger picture over the past 3 months. Over the past year Chemed has delivered a 15.74% total shareholder return. The recent 1 day share price move down 5.16% to US$520.27 contrasts with a 22.01% 90 day share price return, suggesting momentum has cooled slightly after a strong...